House dust mite allergens (HDM allergens) (HDM allergens)

The phrase "Polyclonal IgE/IgG4 and T-cell responses to multiple house dust mite allergens" describes a complex physiological immune profile rather than a single molecular target. It encompasses the adaptive immune system's reaction to proteins derived from house dust mites (HDM), such as Der p 1 and Der f 2 (Thomas et al., 2002, JACI). In sensitized individuals, this involves the production of polyclonal IgE antibodies that trigger mast cell degranulation, leading to allergic inflammation (Galli et al., 2008, Nature). Therapeutic interventions like allergen immunotherapy (AIT) aim to modulate this response by inducing "blocking" IgG4 antibodies and shifting T-cell activity from a pro-allergic Th2 phenotype to a regulatory (Treg) or Th1 phenotype (Akdis & Akdis, 2014, Nature Reviews Immunology). While not a single receptor or enzyme, this integrated immune response is the primary focus of treatments for HDM-induced asthma and allergic rhinitis (Shamji & Durham, 2017, JACI). Monitoring the ratio of specific IgE to IgG4 and T-cell cytokine production serves as a key method for evaluating the efficacy of these immunotherapies (Durham & Penagos, 2016, JACI: In Practice).

Other names

Dermatophagoides allergensHDM-specific immune responsePolyclonal IgE/IgG4 and T-cell responses to HDM

Allergen immunotherapy (AIT) modulates the immune system by inducing peripheral tolerance, shifting T-cell responses from Th2 to Th1/Treg, and promoting the production of IgG4 blocking antibodies that compete with IgE for allergen binding (Akdis & Akdis, 2014, Nature Reviews Immunology).